Charles Schwab’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-406,459
| Closed | -$70M | – | 3621 |
|
|
2021
Q3 | $70M | Buy |
406,459
+15,493
| +4% | +$2.03M | 0.02% | 669 |
|
|
2021
Q2 | $49.1M | Buy |
390,966
+9,660
| +3% | +$1.22M | 0.02% | 881 |
|
|
2021
Q1 | $51.7M | Buy |
381,306
+14,017
| +4% | +$1.81M | 0.02% | 804 |
|
|
2020
Q4 | $47M | Buy |
367,289
+5,780
| +2% | +$678K | 0.02% | 803 |
|
|
2020
Q3 | $40.7M | Buy |
361,509
+120,723
| +50% | +$12M | 0.02% | 765 |
|
|
2020
Q2 | $22.9M | Sell |
240,786
-51,817
| -18% | -$4.99M | 0.01% | 1078 |
|
|
2020
Q1 | $26.3M | Buy |
292,603
+4,064
| +1% | +$316K | 0.02% | 820 |
|
|
2019
Q4 | $15.3M | Buy |
288,539
+6,887
| +2% | +$314K | 0.01% | 1399 |
|
|
2019
Q3 | $11.1M | Buy |
281,652
+19,306
| +7% | +$838K | 0.01% | 1533 |
|
|
2019
Q2 | $10.8M | Buy |
262,346
+15,708
| +6% | +$650K | 0.01% | 1552 |
|
|
2019
Q1 | $11.5M | Buy |
246,638
+34,182
| +16% | +$1.5M | 0.01% | 1500 |
|
|
2018
Q4 | $9.25M | Sell |
212,456
-1,041
| -0.5% | -$52K | 0.01% | 1510 |
|
|
2018
Q3 | $12.2M | Buy |
213,497
+8,257
| +4% | +$406K | 0.01% | 1498 |
|
|
2018
Q2 | $9.96M | Buy |
205,240
+12,969
| +7% | +$473K | 0.01% | 1608 |
|
|
2018
Q1 | $7.52M | Buy |
192,271
+16,718
| +10% | +$711K | 0.01% | 1691 |
|
|
2017
Q4 | $7.45M | Buy |
175,553
+17,601
| +11% | +$660K | 0.01% | 1676 |
|
|
2017
Q3 | $5.89M | Buy |
157,952
+14,110
| +10% | +$490K | 0.01% | 1793 |
|
|
2017
Q2 | $4.37M | Buy |
143,842
+12,001
| +9% | +$348K | ﹤0.01% | 1888 |
|
|
2017
Q1 | $3.49M | Buy |
131,841
+7,335
| +6% | +$193K | ﹤0.01% | 1958 |
|
|
2016
Q4 | $3.18M | Buy |
124,506
+6,709
| +6% | +$213K | ﹤0.01% | 1966 |
|
|
2016
Q3 | $4.26M | Buy |
117,797
+5,740
| +5% | +$190K | 0.01% | 1746 |
|
|
2016
Q2 | $3.81M | Buy |
112,057
+5,634
| +5% | +$183K | ﹤0.01% | 1735 |
|
|
2016
Q1 | $2.81M | Buy |
106,423
+15,094
| +17% | +$439K | ﹤0.01% | 1872 |
|
|
2015
Q4 | $4.45M | Buy |
91,329
+15,237
| +20% | +$548K | 0.01% | 1600 |
|
|
2015
Q3 | $1.9M | Buy |
76,092
+30,037
| +65% | +$903K | ﹤0.01% | 2101 |
|
|
2015
Q2 | $1.46M | Buy |
46,055
+6,818
| +17% | +$220K | ﹤0.01% | 2244 |
|
|
2015
Q1 | $1.49M | Buy |
39,237
+1,437
| +4% | +$57.1K | ﹤0.01% | 2214 |
|
|
2014
Q4 | $1.47M | Buy |
37,800
+8,455
| +29% | +$295K | ﹤0.01% | 2174 |
|
|
2014
Q3 | $888K | Buy |
29,345
+306
| +1% | +$8.62K | ﹤0.01% | 2354 |
|
|
2014
Q2 | $987K | Buy |
29,039
+11,904
| +69% | +$398K | ﹤0.01% | 2326 |
|
|
2014
Q1 | $592K | Buy |
17,135
+3,160
| +23% | +$143K | ﹤0.01% | 2525 |
|
|
2013
Q4 | $554K | Buy |
+13,975
| New | +$337K | ﹤0.01% | 2554 |
|
Charles Schwab's XLRN Position: Q4 2021 in Review
Charles Schwab sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 406,459 shares — an estimated $70M sold.
Charles Schwab first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $70M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Charles Schwab reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Charles Schwab sold 406,459 Acceleron Pharma shares in Q4 2021, an estimated $70M.
- Charles Schwab first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Charles Schwab's Acceleron Pharma position peaked at $70M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Charles Schwab's 13F filing for Q4 2021, filed 11 Feb 2022.